Hospital Center of Tras-os-Montes and Alto Douro, Vila Real (Portugal)
7
presentations
0
follower
7
more
presentations
in this session
Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy